EUVIMEDOpdag EUVIMED
Crossref

Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model

Joseph A Grillo iD, Douglas McNair, Ping Zhao

Biopharmaceutics & Drug Disposition · 2023-08 · 44 (4) · 344-347

DOI: 10.1002/bdd.2369 ↗

At a glance

Journal article in Biopharmaceutics & Drug Disposition, published online on 2023-06-22. Written by Joseph A Grillo and 2 co-authors. Institution: Labeling and Health Communication, Office of Clinical Pharmacology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Major MEDLINE topics: Cytochrome P-450 CYP3A Inhibitors, Renal Insufficiency, Chronic. Cited 8 times so far (Crossref); 7 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Today real word data (RWD) are playing a greater role in informing health care decisions. A physiologically based pharmacokinetic model (PBPK) and observed exposure–risk relationship predicted an increased bleeding risk induced by rivaroxaban (RXB) in patients with mild to moderate chronic kidney disease (CKD) taking concomitant medications that are combined Pgp‐CYP3A inhibitors. In this commentary, we explore the potential use of RWD to assess the clinical consequence of this complex drug–drug interaction predicted from PBPK. This is a retrospective, case control, pilot study using a RWD dataset of 896,728 patients with mild to moderate chronic kidney disease and rivaroxaban use that was refined based upon combined Pgp‐CYP3A inhibitor exposure and report of drug‐induced bleeding (DIB). The odds ratio of patients with mild to moderate chronic kidney disease taking rivaroxaban with or without concurrent Pgp‐CYP3A inhibitor use having a DIB was calculated. The odds ratio for DIB was 2.04 (CI 95 1.82, 2.3; p < 0.001) suggesting an approximate doubling of bleeding risk which is consistent with the rivaroxaban exposure changes predicted by the published PBPK model and observed exposure–risk relationship. This exploratory analysis demonstrated the potential utility of RWD to assess model‐based predictions as part of a drugs life cycle management.

Subjects

MeSH terms (MEDLINE)

Cytochrome P-450 CYP3A InhibitorsRenal Insufficiency, ChronicHumansRivaroxabanRetrospective StudiesPilot ProjectsDrug InteractionsModels, BiologicalCytochrome P-450 CYP3AComputer Simulation

Author keywords

MIDD (model-informed drug development)PBPKclinical pharmacologydrug-drug interactionsmodeling and simulationpharmacokinetics and drug metabolismreal world data

Substances

Cytochrome P-450 CYP3A InhibitorsRivaroxabanCytochrome P-450 CYP3A

Authors and institutions

  • Labeling and Health Communication, Office of Clinical Pharmacology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Quantitative Sciences, Global Health - Integrated Development, Bill & Melinda Gates Foundation, University of Washington, Seattle, Washington, USA.
  • Bill & Melinda Gates Foundation, University of Washington, Seattle, Washington, USA.

ORCID profiles: Joseph A Grillo

Cite

APA

Grillo, J. A., McNair, D., & Zhao, P. (2023). Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model. Biopharmaceutics & Drug Disposition, 44(4), 344-347. https://doi.org/10.1002/bdd.2369

Vancouver

Grillo JA, McNair D, Zhao P. Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model. Biopharmaceutics & Drug Disposition. 2023;44(4):344-347. doi:10.1002/bdd.2369

BibTeX
@article{Grillo2023,
  author = {Grillo, Joseph A and McNair, Douglas and Zhao, Ping},
  title = {Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2023},
  volume = {44},
  number = {4},
  pages = {344--347},
  doi = {10.1002/bdd.2369}
}
Start for free →